Krka Launches First Line Antibiotic Cladaxxa® In Its Companion Animal Range
Krka has extended its companion animal product range with the launch of Cladaxxa®, a broad-spectrum antibiotic offering proven efficacy in the targeted treatment of respiratory, digestive, urinary, skin and dental infections in dogs and cats.
Offering bioequivalence to the market reference product¹, Cladaxxa is a combined amoxicillin/clavulanic antibiotic, designed for first line treatment of bacterial infections2. This new range is available in three strengths of flavoured tablet, with the 200/50 mg formulation also licenced for cats to reduce the tablet burden in larger breeds.
Cladaxxa is presented in Krka’s unique blister design packaging to protect the clavulanic acid, which is highly sensitive to moisture. Ready-scored tablets support accurate dosing and optimal use is also ensured as halved tablets can be returned to the protective blister packaging to be used within the following 24 hours. It is offered in packs of 60 or 100 tablets to offer maximum efficiency for practices.
Commenting on the range launch, Krka’s National Sales Manager Will Ridgway, said: "Treating bacterial infections is an important everyday task for vets in practice. Cladaxxa is a great example of Krka using its expertise in end to end product design to deliver efficacy and value to our customers. We hope they will find Cladaxxa an advantageous solution in treating these patients.”
Ned Flaxman, General Manager of Krka UK, added: “In addition to supplying reliable solutions combined with commercial simplicity for our veterinary customers, Krka is looking to the future. We are leveraging our proficiency in product development and vertical supply chains to drive further growth in our animal health portfolio to ensure that, even in turbulent times, we deliver accessible and affordable treatments for all.”
Krka UK Ltd is the fastest growing animal health company in the UK (source: Kynetec UK Vet Data November 2021). A subsidiary of Slovenia-based Krka, d. d. Novo Mesto; the animal health product portfolio consists of high-quality generic pharmaceuticals for both companion animal and food producing animals covering parasite control, antibiotics and pain relief. It includes the Milprazon CHEWABLE and Prinocate ranges, for parasite prevention and treatment in cats and dogs, and Tolracol for coccidiosis management in cows and sheep.
¹ Comparative, single-dose, 2-way cross-over bioavailability study of two Amoxicillin/Clavulanic acid 200 mg/50 mg tablet formulations in dogs under fasting condition. Krka study code: 18-V/50. Krka, d.d., Novo mesto; Šmarješka cesta 6, 8501 Novo mesto, Slovenia. / Comparative, single-dose, 2-way cross-over bioavailability study on two amoxicillin/clavulanic acid (40 mg/10 mg tablets) formulations in fasting in cats. Krka study code: 19-V/56. Krka, d.d., Novo mesto; Šmarješka cesta 6, 8501 Novo mesto, Slovenia. 2 J. E.maddison, A.David, J.Watson, J. Elliott: Small Animal Clinical Pharmacology (Second Edition), 2008, Chapter 8 - Antibacterial drugs, Pages 148-85. 3. Gomez-Poveda B and Moreno MA (2018) Antimicrobial Prescriptions for Dogs in the Capital of Spain. Front. Vet. Sci. 5:309. doi: 10.3389/fvets.2018.00309. 4. The United States Pharmacopeial Convention. Amoxicillin and Clavulanate (Veterinary-Systemic). Contin Educ Pract Vet 2007; 1-4.
2 Refer to SPC for full details.
For further information:
Rebecca George, George PR
Tel: 01449 737281/07974 161108
More from KRKA